Effectiveness of administering zinc acetate hydrate to patients with inflammatory bowel disease and zinc deficiency: a retrospective observational two-center study
- Author:
Kensuke SAKURAI
1
;
Shigeru FURUKAWA
;
Takehiko KATSURADA
;
Shinsuke OTAGIRI
;
Kana YAMANASHI
;
Kazunori NAGASHIMA
;
Reizo ONISHI
;
Keiji YAGISAWA
;
Haruto NISHIMURA
;
Takahiro ITO
;
Atsuo MAEMOTO
;
Naoya SAKAMOTO
Author Information
- Publication Type:Original Article
- From:Intestinal Research 2022;20(1):78-89
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background/Aims:Inflammatory bowel disease (IBD) patients frequently have zinc deficiency. IBD patients with zinc deficiency have higher risks of IBD-related hospitalization, complications, and requiring surgery. This study aimed to examine the effectiveness of zinc acetate hydrate (ZAH; Nobelzin) in IBD patients with zinc deficiency.
Methods:IBD patients with zinc deficiency who received ZAH from March 2017 to April 2020 were registered in this two-center, retrospective, observational study. Changes in serum zinc levels and disease activity (Crohn’s Disease Activity Index [CDAI]) before and after ZAH administration were analyzed.
Results:Fifty-one patients with Crohn’s disease (CD, n = 40) or ulcerative colitis (UC, n = 11) were registered. Median serum zinc level and median CDAI scores significantly improved (55.5–91.0 μg/dL, P< 0.001; 171.5–129, P< 0.001, respectively) in CD patients 4 weeks after starting ZAH administration. Similarly, median serum zinc levels and CDAI scores significantly improved (57.0–81.0 μg/dL, P< 0.001; 177–148, P= 0.012, respectively) 20 weeks after starting ZAH administration. Similar investigations were conducted in groups where no treatment change, other than ZAH administration, was implemented; significant improvements were observed in both serum zinc level and CDAI scores. Median serum zinc levels in UC patients 4 weeks after starting ZAH administration significantly improved from 63.0 to 94.0 μg/dL (P= 0.002), but no significant changes in disease activity were observed. One patient experienced side effects of abdominal discomfort and nausea.
Conclusions:ZAH administration is effective in improving zinc deficiency and may contribute to improving disease activity in IBD.
